Pfizer at the 27th Annual J.P. Morgan Healthcare Conference


Published on

Published in: Economy & Finance
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Pfizer at the 27th Annual J.P. Morgan Healthcare Conference

  1. 1. 2009 JP Morgan Conference Martin Mackay President, PGRD January 13, 2009
  2. 2. Forward-Looking Statements Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K These reports are available on our website at in the quot;Investors—SEC Filingsquot; section
  3. 3. Martin Mackay President, PGRD
  4. 4. PGRD’s Five Strategic Elements 1 Aggressively Deliver the Phase 2 and Phase 3 Portfolio 2 Prioritize Our Portfolio to Deliver the Most Value 3 Become a Top-Tier Biotherapeutics Company 4 Dramatically Raise the Bar on Productivity 5 Pursue the Best External Science
  5. 5. 2008 Achievements Global Submissions Global Approvals Fesoterodine Overactive Bladder (US) Fablyn Osteoporosis Treatment (Europe) Maraviroc HIV Treatment in Lyrica Post Herpetic Neuralgia (Japan) Experienced Patients (Japan) Xalacom Glaucoma (Japan) Macugen Age-Related Macular Maraviroc HIV Treatment Experienced Degeneration (Japan) Patients (Japan) Rifabutin Bacterial Infections (Japan) Maraviroc HIV Treatment Naïve Patients Sutent Gastrointestinal Stromal Tumor (US) (Japan) Lyrica Oral Solution (Europe) Champix Smoking Cessation (Japan) Revatio IV Formulation (US and Europe) Genotropin Short Stature/Growth Geodon Bipolar Mania Maintenance Adult Problems (Japan) (US) Zithromax SR Peds Bacterial Infections Geodon Peds (US and Europe) (US) Norvasc 10mg dosing (Japan) Sutent Renal Cell Cancer (Japan) Lyrica Fibromyalgia (Europe) Revatio Pulmonary Arterial Hypertension (Japan) Zithromax SR Bacterial Infections (Japan)
  6. 6. 2008 Achievements Business Development Advanced to Phase 3 Dimebon Alzheimer’s Dementia Auxilium Xiaflex for Dupuytren’s contracture and Peyronie’s Disease Tanezumab OA Signs and Symptoms Sigma-Tau Eurartesim for malaria CP-751871 Non-Small Cell Lung Cancer Medivation Dimebon for Alzheimer’s and Axitinib Pancreatic Cancer Huntington’s Disease Axitinib 2nd Line Renal Cell Carcinoma UCB Cyclofluidic (US and Japan) Eyecyte New Paradigm of Drug Lyrica Restless Leg Syndrome Development Xalatan Peds Glaucoma UPENN Collaboration with UPENN Sutent Prostate Cancer School of Medicine Sutent Hepatocellular Cancer UCSF Alliance to Advance Broad Range Apixaban VTE Treatment of Research Sutent Colorectal Cancer Five Prime Therapeutics Oncology and Gabapentin Peds Epilepsy Diabetes Collaboration Geodon Adj use in Bipolar Depression AVANT/Celldex CDX-110 Glioblastoma Multiforme Maraviroc Peds HIV Encysive Acquisition Early Portfolio Serenix Acquisition Scil Novel Cartilage Growth Factor 10 POCs, 19 FIPs, 26 FIHs
  7. 7. Innovating Our Model with Smaller, More Accountable Business Units Primary Specialty Established Emerging Animal Oncology Care Care Products Markets Health Business Units Research and Biotherapeutics & Late-Stage Sales & Bioinnovation Center Medical Development Marketing Manufacturing Customer Focused Partner Lines Enabling Functions
  8. 8. Advancing Compounds in the Pipeline Pipeline as of Sept 30, 2008 Over 300 Total Phase 1 Phase 2 Phase 3 In Reg. Discovery 50 38 25 1 114 Projects Goals (Announced March 2008) 15–20 Phase 3 starts in 2008 – 2009 24–28 Programs in Phase 3 by end of 2009 15–20 Submissions 2010 – 2012 On-Track to Meet These Goals
  9. 9. Recent Disease Area Decisions Disease Area Focus Disease Area Exits* Alzheimer’s Disease Anemia Diabetes Atherosclerosis/Hyperlipidemia Inflammation/Immunology Bone Health/Frailty Oncology Gastrointestinal Pain Heart Failure Psychosis Liver Fibrosis Asthma/COPD Muscle Genitourinary Obesity Infectious Disease Osteoarthritis Ophthalmology Peripheral Arterial Disease *Does not affect our portfolio of marketed products, the development of compounds in Phase 3 or any launches planned in the next three years
  10. 10. Biotherapeutics and Bioinnovation Center Federation of Technology-aligned Research Units and Biologic-generating Companies San Francisco fabrus UCSF/QB3 Ambryx FivePrime Rinat Antibodies Scripps MGH CovX RTC Wint- San Diego Boston BBC RGo herix RNAi Peptides Isogenica Bend PRM* Stem Cells Research Unit Novocell Collaborations Incubator Portfolio Company EyeCyte Europe *Collaboration with PGRD
  11. 11. Biotherapeutics in the Pipeline Research Development Marketed 72 17 5 $1.2B Est. 2008 Revenues Diverse Portfolio 9 TAs (interferon beta-1a) (dalteparin sodium injection) 6 Modalities 53 MAbs 9 Vaccines
  12. 12. Today’s Phase 3 Portfolio axitinib – Pancreatic Cancer esreboxetine – Fibromyalgia apixaban – VTE Prevention Zithromax/chloro – Malaria Thelin – Pulmonary Hypertension Dalbavancin – Skin & Skin NMEs Structure Infections Dimebon – Alzheimer’s Disease tanezumab –OA Pain CP-751871 – Lung Cancer Xiaflex – Dupuytren’s PD-332334 – GAD contracture / New apixaban – Atrial Fibrillation Indications apixaban – VTE Treatment axitinib – Renal Cell Cancer
  13. 13. Rebuilding the Phase 3 Portfolio Number of Phase 3 Programs 24–28 26 16 8 Jan '07 Mar '08 Dec '08 Dec '09 Analyst Day Actual Projected NMEs New Indications
  14. 14. Select Late Stage Candidates Tanezumab (NGF Antibody) Pain CP-690550 (JAK3 Inhibitor) Rheumatoid Arthritis Dimebon (MPTP Modulator) Alzheimer’s Disease CP-751871 (IGF1R Antibody) Lung Cancer Sutent (Multiple Tyrosine Kinase Inh) Breast Cancer
  15. 15. Tanezumab: Overview Acquired as part of Rinat deal Heavy Humanized, IgG2 MAb Chain High specificity and affinity for NGF Fast to market strategy with Osteoarthritis (OA) NGF Clinical efficacy demonstrated in OA 5 minute I.V. administration Low projected dose < 10 mg once every 8 wks Light Phase 3 program: Nov 2008 Chain Additional Phase 2 studies Completed; Chronic low back pain; Results at the 2009 American Pain Society Meeting Ongoing: Post-herpetic neuralgia, interstitial cystitis, Japan OA I.V. bridging; S.C. PK Initiating: Prostatitis; metastatic bone pain, endometriosis
  16. 16. Tanezumab: Walking Knee Pain (Mean Change ± Standard Error) Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Mean Change from Baseline 0 Over Weeks 1–16 (SE) Change in VAS from Baseline -10 Placebo -15.5 (2.6) Tanezumab -32.1 (2.5)* LS Mean (SE), mm 10 µg/kg -20 Tanezumab -36.0 (2.5)* 25 µg/kg -30 Tanezumab -31.0 (2.6)* 50 µg/kg -40 Tanezumab -42.5 (2.5)* 100 µg/kg -50 Tanezumab -45.2 (2.6)* 200 µg/kg -60 Study Drug Study Drug Administration Administration *P<.0001 vs. placebo
  17. 17. CP-690550 (JAK-3): Overview Small molecule discovered in Evidence of efficacy in multiple Groton Labs human diseases of immunological dysregulation Key Milestones RA, kidney allograft rejection, and psoriasis, all have continuing FIH – March 2002 Phase 2 programs POM – June 2004 Phase 2 program also FIP – Dec 2004 undertaken in IBD POC – July 2006 Rheumatoid Arthritis (RA) chosen as lead indication Scheduled for Phase 3 start March 2009
  18. 18. CP-690550 (JAK-3): Positive Primary Efficacy Results Phase 2 RA Studies 12 Weeks Plus Background MTX in 6 Weeks Monotherapy in Patients Patients with Inadequate Response Who Had Failed MTX or a Tnfi to a Stable Dose of MTX
  19. 19. Dimebon: Overview Co-development with Medivation, Inc. Dimebon primary mechanism of action Enhances mitochondrial function Other pathways may also contribute In development for AD (Phase 3) and Huntington’s disease (HD, Phase 2) Clinical efficacy demonstrated across 5 clinical endpoints Improvement in cognitive endpoint in Phase 2 HD Phase 3 Studies Ongoing: 6 month monotherapy in mild-moderate AD (CONNECTION) Several others initiating in 2009
  20. 20. Dimebon: Affects Cognition in Mild-to-Moderate AD Treatment p = 0.0077 p < 0.0001 p < 0.0001 p < 0.0001 Effect 2.0 4.0 5.9 6.9 –3.0 Mean Change From Baseline –2.0 Clinical –1.0 Improvement Score ADS-cog 0.0 1.0 2.0 3.0 4.0 5.0 Dimebon (n = 89) Clinical Deterioration 6.0 Placebo (n = 94) Baseline 12 26 39 52 Week * Similar results were seen with the MMSE over 1 year Doody RS, et al. Lancet. 2008;372:207-215.
  21. 21. CP-751871 (figitumumab): Overview Anti-IGF-1R mAb discovered in Groton Labs Fully human, IgG2 MAb First-in-class opportunity in highly competitive arena First selective anti-IGF mAb to enter human trials First to generate published Phase 2 data First to start formal Ph3 trials in mid-2008 Over 1000 patients have participated in CP-751 clinical trials Very well tolerated with no dose-limiting toxicity seen to date Combinable with a wide variety of currently used standard of care agents Promising signs of clinical activity in lung cancer and sarcoma On-going Ph3 registration program in lung cancer Ph2 investigations of risk/benefit on-going in breast, colorectal, prostate and sarcoma IGF-1R – Receptor on Cell Surface Triggering Key Pathways That Drive Cancer Cell Survival
  22. 22. CP-751871: Plus Chemotherapy in 1st Line NSCLC Responses in Bulky Squamous Tumors US Spain Italy October 2005 August 2007 November 2007 February 2006 October 2007 April 2008 Ref: Karp et al, ASCO 2008
  23. 23. Sutent: Potential New Indications Expected to Drive Value Colorectal es nu ve Non-Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time
  24. 24. Sutent: Breast Cancer Clinical anti-tumor activity in breast cancer Demonstrated in Phase 2, single-agent study in heavily pre- treated, advanced disease (ASCO, 2005) Preclinical and clinical rationale to combine and improve treatment with chemotherapy – Example: Phase 1 combination docetaxel + SU (n = 22) – Objective Response Rate 72% (SABC, 2007) Multiple Phase 1/2 single-agent and combination studies with docetaxel, paclitaxel, capecitabine, trastuzumab – HER-2 (-) breast cancer – HER-2 (+) breast cancer – Triple-negative breast cancer – Locally-recurrent breast cancer
  25. 25. Commitments On Track to Meet our March 5, 2008 Commitments 15–20 Phase 3 starts by end of 2009 24–28 Phase 3 programs by end of 2009 15–20 Submissions by 2010–2012
  26. 26. Working Together to Progress Assets, Programs and Technologies Areas of Interest Types of Relationships Alzheimer’s Infectious Disease Licensing Disease Ophthalmology Co-develop/Co-promote Diabetes Smoking Cessation Alliances Inflammation & Thrombosis Venture Investments Immunology Biotherapeutics M&A Oncology Vaccines Out Licensing Pain Science & Academic Psychosis Technologies Asthma/COPD Regenerative Genitourinary Medicine